Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data - Takeaways - MDSpire

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

  • By

  • Mattia Alberto Di Civita

  • Daniele Marinelli

  • Valerio Marco Michetti

  • Adele Artemi

  • Andrea Ballario

  • Andrea Torchia

  • Laura Pappalardo

  • Martina Pecoraro

  • Iolanda Speranza

  • Alessandro Sciarra

  • Valeria Panebianco

  • Michela Roberto

  • Daniele Santini

  • January 8, 2026

  • 0 min

Share

  • 1

    Renal cell carcinoma (RCC) is a prevalent cancer, with 25-30% of patients presenting with metastatic disease at diagnosis.

  • 2

    Combination immunotherapy has significantly improved survival outcomes in metastatic RCC compared to traditional monotherapy.

  • 3

    Patients with favorable risk scores may not benefit significantly from immunotherapy combinations over sunitinib monotherapy.

  • 4

    This meta-analysis focuses on evaluating first-line combination therapies for advanced RCC in patients with favorable prognostic scores.

  • 5

    The study aims to identify optimal treatment strategies among various ICI-TKI combinations for favorable risk patients.

Original Source(s)

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

  • by Mattia Alberto Di Civita, Daniele Marinelli, Valerio Marco Michetti, Adele Artemi, Andrea Ballario, Andrea Torchia, Laura Pappalardo, Martina Pecoraro, Iolanda Speranza, Alessandro Sciarra, Valeria Panebianco, Michela Roberto, Daniele Santini

  • January 8, 2026

Related Content

Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy

Mortality Patterns in U.S. Patients with Kidney Malignancies: A Retrospective Analysis from 1999 to 2023

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

  • 1 min